Abstract
Background
Since there is little information about the naturalistic way of treatment in daily European practice, the Attention–Deficit Hyperactivity Disorder Observational Research in Europe (ADORE) project was designed as a prospective, non–interventional study of approximately 1,500 patients observed by approximately 300 investigators in various European regions.
Objective
The primary objective is the description of the relationship between treatment regimen prescribed and quality of life in ADHD patients over a two–year period.
Method
The naturalistic care provided and the outcomes (psychopathology, quality of life) are recorded at 7 data collection points.
Results
The present preliminary report provides data on the first 315 patients who were included in the study by the beginning of January 2004. The data provide an impression of the sample characteristics, the clinical diversity, and the effects of ADHD on school careers and social activities. Furthermore, treatment information dealing with the time both before and at baseline is given.
Conclusion
Even with this limited sample the negative effects on psychosocial development and quality of life in ADHD children are apparent.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Buitelaar JK (2002) Epidemiological aspects: what have we learned over the last decade? In: Sandberg S (ed) Hyperactivity and Attention Disorder of Childhood. Cambridge University Press, Cambridge
Buitelaar JK, Montgomery SA, van Zwieten- Boot BJ, on behalf of the Consensus Committee Brown T, Findling RL, Gillberg C, Lecrubier Y, Saint Raymond A, Spencer T, Steinhausen HC (2003) Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 13:297–304
Danckaerts M, Heptinstall E, Chadwick O, Taylor E (1999) Self-report of attention deficit and hyperactivity disorder in adolescents. Psychopathology 32:81–92
Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie (eds) (2000) Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Deutscher Ärzte Verlag, Koeln
DuPaul GJ, Power TJ, et al. (1988) ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. The Guilford Press, New York
Goodman R (1997) The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 38:581–586
Guy, W (ed) (1976) Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. National Institute of Mental Health, Rockville MD
Klasen H, Goodman R (2000) Parents and GPs at cross-purposes over hyperactivity: a qualitative study of possible barriers to treatment. Br J Gen Pract 50:199–202
Nederlandse Vereniging voor Psychiatrie en Sectie Kinder- en Jeugdpsychiatrie (NVP) (1999) Richtlijn diagnostiek en behandeling ADHD (kinderen en adolescenten). Uitgeverij Boom, Bestuur Nederlandse Vereniging voor Psychiatrie Amsterdam
Riley AW, Forrest C, Starfield B, Rebok G, Green B, Robertson J (2001) Child Health and Illness Profile – Child Edition (CHIP-CE™). The John Hopkins University, Baltimore MD
Sergeant J, Steinhausen HC (1992) European perspectives on hyperkinetic disorder. Eur Child Adolesc Psychiatry 1:34–41
Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) A children’s global assessment scale (C- GAS). Arch Gen Psychiatry 40:1228–1231
Steinhausen HC, Metzke CW, Meier M, Kannenberg R (1998) Prevalence of child and adolescent psychiatric disorders: the Zurich Epidemiological Study. Acta Psychiatr Scand 98:262–271
Swanson JM, Sergeant J, Taylor E, Sonuga-Barke E, Jensen P, Cantwell DP ( Swanson) Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351:429–433
Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 13:I7–I30
Taylor E, Chadwick O, Heptinstall E, Danckaerts M (1996) Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry 35:1213–1226
Taylor E, Sandberg S, Thorley G, Giles S (1991) The epidemiology of childhood hyperactivity. Maudsley Monographs No. 33. Institute of Psychiatry, London
Taylor E, Sergeant J, Döpfner M, Gunning B, Overmeyer S, Möbius HJ, Eisert HG (1998) Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry 7:184–200
Verhulst FC, van der Ende J, Ferdinand RF, Kasius MC (1997) The prevalence of DSM-III-R diagnoses in a national sample of Dutch adolescents. Arch Gen Psychiatry 54:329–336
Woodward L, Dowdney L, Taylor E (1997) Child and family factors influencing the clinical referral of children with hyperactivity: a research note. J Child Psychol Psychiatry 38:479–485
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomised placebo-controlled, dose response study. Pediatrics 108 (5):E83
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Members of the ADORE study group: Baldursson G, Coghill D, Curatolo P, Dalsgaard S,Döpfner M,Falissard B,Forrest CB,Hervas A, Le Heuzey MF, Lorenzo MJM, Nøvik TS, Pereira RR, Preuss U, Rasmussen P, Rothenberger A, Riley AW, Spiel G, Steinhausen HC, Vlasveld L. The ADORE study has the financial support of Eli Lilly and Company Limited.
Rights and permissions
About this article
Cite this article
Ralston, S.J., Lorenzo, M.J.M. & and the ADORE study group. ADORE – Attention–Deficit Hyperactivity Disorder Observational Research in Europe. European Child & Adolescent Psychiatry 13 (Suppl 1), i36–i42 (2004). https://doi.org/10.1007/s00787-004-1004-8
Issue Date:
DOI: https://doi.org/10.1007/s00787-004-1004-8